Financial Performance - The company's revenue for Q1 2025 was CNY 1,326,616,043.20, a slight increase of 0.05% compared to CNY 1,325,969,392.93 in the same period last year[5] - Net profit attributable to shareholders was CNY 153,161,633.89, representing a growth of 4.83% from CNY 146,099,164.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses decreased by 13.55% to CNY 95,369,685.69 from CNY 110,319,647.03 in the previous year[5] - Total revenue for the current period reached ¥1,326,616,043.20, slightly up from ¥1,325,969,392.93 in the previous period, indicating a growth of approximately 0.05%[22] - The net profit for the current period is CNY 138,229,631.62, an increase from CNY 117,548,462.21 in the previous period, representing a growth of approximately 17.4%[23] - The total comprehensive income for the current period is CNY 158,904,733.40, compared to CNY 103,628,790.72 in the previous period, indicating a significant increase of about 53.4%[23] - The basic and diluted earnings per share for the current period are both CNY 0.1259, up from CNY 0.1201 in the previous period, representing an increase of approximately 4.8%[23] Cash Flow and Assets - Operating cash flow for the period was CNY 182,335,417.29, up by 0.83% from CNY 180,839,724.48 in the same quarter last year[5] - Cash and cash equivalents decreased to ¥874,295,606.70 from ¥889,388,507.75, a decline of approximately 1.03%[18] - Cash and cash equivalents at the end of the period decreased to CNY 768,385,206.69 from CNY 688,839,805.94, reflecting a decline of approximately 14.5%[26] - The net cash outflow from investing activities for the current period is CNY -107,357,698.14, compared to CNY -76,271,060.87 in the previous period, reflecting a larger outflow[25] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 12,510,887,760.92, an increase of 1.83% from CNY 12,285,788,088.75 at the end of the previous year[5] - Total liabilities increased to ¥3,923,026,883.24 from ¥3,858,992,750.77, marking a rise of approximately 1.67%[19] - The company's equity attributable to shareholders increased by 2.06% to CNY 8,697,424,767.68 from CNY 8,521,867,867.56 at the end of the last year[5] - The company's equity attributable to shareholders rose to ¥8,697,424,767.68 from ¥8,521,867,867.56, an increase of about 2.06%[20] Operating Costs and Expenses - Total operating costs increased to ¥1,200,723,203.71 from ¥1,189,455,724.43, reflecting a rise of about 0.22%[22] - Research and development expenses for the current period were ¥63,503,366.31, compared to ¥59,876,908.40 in the previous period, indicating an increase of approximately 6.93%[22] - The company reported a tax expense of CNY 18,453,067.29, down from CNY 41,365,369.65 in the previous period, showing a decrease of about 55.5%[23] - Financial expenses decreased by 48.66% to CNY 8,896,429.66, attributed to increased exchange gains and reduced interest expenses[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,858, with the largest shareholder holding 40.82% of the shares[11] - The top ten unrestricted shareholders hold a total of 124,131,577 shares, with Cheng Xianfeng being the largest shareholder[12] - The company has not reported any changes in the participation of top shareholders in margin trading activities[13] - The company has not identified any related party relationships among shareholders beyond those disclosed[12] - The total number of shares held by the top ten unrestricted shareholders includes significant stakes from various investment funds and individuals[12] Strategic Developments - The company received government subsidies amounting to CNY 58,918,080.80 during the reporting period, which significantly contributed to its financial performance[6] - The company continues to focus on expanding its product portfolio and enhancing its market presence through strategic initiatives[14] - The subsidiary Yifan Pharmaceutical Co., Ltd. received a drug registration certificate for Ambrisentan oral solution on March 10, 2025[14] - The subsidiary Yiyisheng Biopharmaceutical (Beijing) Co., Ltd. received approval for a supplemental application for Aibegesitin α injection on March 21, 2025, changing the administration timing[14] - Two subsidiaries achieved high-tech enterprise certification in February 2025, enhancing their innovation capabilities[15] Future Outlook - The company expects to turn a profit in 2024, as indicated in the earnings forecast released on January 24, 2025[13] - The controlling shareholder, Cheng Xianfeng, has pledged part of his shares as of February 20, 2025, indicating potential liquidity management[16]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 15, compared to the last closing price of 11.43 [1][8]. Core Insights - The company achieved significant growth in both revenue and profit, with a 2024 revenue of 5.16 billion, representing a year-on-year increase of 26.84%, and a net profit of 386 million, up 170.04% year-on-year [4][5]. - The commercialization of the product Yilishu is progressing well, with approvals for sale in 34 countries, including China, the US, and the EU [7]. - The company is actively advancing its pipeline of innovative drugs, with ongoing clinical trials for F-652 and other projects [7]. Financial Performance Summary - In 2024, the company reported a revenue of 5.16 billion, with a 26.84% increase year-on-year, driven by the approval and sales of self-developed and imported pharmaceutical products [5]. - The gross profit for 2024 was 2.447 billion, with a gross margin of 47.42%, slightly down by 0.42 percentage points from the previous year [6]. - The company’s net profit for 2024 was 386 million, with a significant increase of 170.04% year-on-year, and a non-recurring net profit of 248 million, up 146.58% [5][10]. Future Earnings Forecast - The company is projected to achieve revenues of 6.42 billion, 7.42 billion, and 8.52 billion in 2025, 2026, and 2027, respectively, with growth rates of 24.40%, 15.70%, and 14.80% [8][10]. - The forecasted net profits for the same years are 721 million, 912 million, and 1.13 billion, with growth rates of 86.80%, 26.50%, and 24.30% [8][10]. - The projected price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 19, 15, and 12, respectively [8].

Core Viewpoint - The company has demonstrated significant growth and profitability in 2024, achieving a revenue of 5.16 billion yuan and a net profit of 386 million yuan, driven by its "innovation + internationalization" strategy [1][2]. Group 1: Financial Performance - In 2024, the company reported a total revenue of 5.16 billion yuan, marking a year-on-year increase of 26.84% [1]. - The net profit attributable to shareholders reached 386 million yuan, successfully turning around from a loss [1]. - The pharmaceutical segment generated 4.26 billion yuan in revenue, accounting for 82.56% of total revenue, with a significant year-on-year growth [2]. Group 2: Product and Market Performance - The company's proprietary pharmaceutical products (including imports) achieved revenue of 3.66 billion yuan, a substantial increase of 50.64% year-on-year [2]. - In the domestic market, 30 proprietary products generated over 10 million yuan in sales, totaling 2.998 billion yuan, which is 95.16% of domestic proprietary revenue [2]. - The company’s international sales reached 735 million yuan, reflecting an 18.82% increase year-on-year, with 13 products exceeding 10 million yuan in sales [2]. Group 3: Innovation and R&D - The company has established a robust international R&D and production system, with its first large molecule innovative drug, Yili Shu, approved in multiple countries [3]. - Over the past decade, the company has invested 4.465 billion yuan in drug innovation and R&D [4]. - The company has 17 ongoing projects in traditional Chinese medicine and has completed 85 key milestones in small molecule drug development, a 13.3% increase from 2023 [5]. Group 4: Global Marketing and Future Strategy - The company has built a comprehensive marketing network, with 332 drug approvals in the domestic market and 43 product rights in international markets [6]. - The company plans to enhance its global presence by focusing on the U.S., Brazil, and Middle Eastern markets for its innovative products [7]. - In 2025, the company aims to deepen its focus on chronic diseases and expand its product offerings while optimizing its global production platform [8].

Shareholding Reduction Announcements - MEI TUNG (CHINA) LIMITED plans to reduce its shareholding in Helen Zhe by up to 22.09 million shares, representing 2.12% of the total share capital after excluding repurchased shares [1] - Shandong Railway Development Fund plans to reduce its shareholding in Century Rui Er by up to 17.55 million shares, representing 3% of the total share capital [1] - Wu Baigeng plans to reduce his shareholding in Pinwo Food by up to 2.97 million shares, representing 3% of the total share capital [1] - Huayuan International Land Port Group plans to reduce its shareholding in Phoenix Shipping by up to 30.36 million shares, representing 3% of the total share capital [3] Financial Performance Reports - United Chemical reported a revenue of 535 million yuan for 2024, a year-on-year increase of 24.80%, and a net profit of 56.43 million yuan, up 66.81% [5] - Huitong Technology achieved a revenue of 662 million yuan, a year-on-year increase of 11.84%, and a net profit of 108 million yuan, up 9.30% [7] - Guangji Pharmaceutical reported a revenue of 639 million yuan, a year-on-year decrease of 13.42%, and a net loss of 295 million yuan [8] - Anshuo Information achieved a revenue of 990 million yuan, a year-on-year increase of 11.53%, and a net profit of 15.09 million yuan, up 132.78% [9] - Yifan Pharmaceutical reported a revenue of 5.16 billion yuan, a year-on-year increase of 26.84%, and a net profit of 386 million yuan, up 170.04% [10] - Hongri Pharmaceutical reported a revenue of 5.78 billion yuan, a year-on-year decrease of 5.34%, and a net profit of 21.47 million yuan, down 95.76% [11] - Zhonglan Environmental reported a revenue of 646 million yuan, a year-on-year decrease of 22.75%, and a net profit of 13.10 million yuan, down 36.12% [13] - Feilu Co. reported a revenue of 518 million yuan, a year-on-year decrease of 37.16%, and a net loss of 140 million yuan [14] - China Great Wall reported a revenue of 14.20 billion yuan, a year-on-year increase of 5.83%, and a net loss of 1.48 billion yuan [15] - Nanshan A reported a revenue of 15.45 billion yuan, a year-on-year decrease of 15.06%, and a net profit of 267 million yuan, down 83.89% [16] - Yawen Co. reported a revenue of 2.06 billion yuan, a year-on-year increase of 6.70%, and a net profit of 75 million yuan, down 24.13% [17] - Jinlong Co. reported a revenue of 663 million yuan, a year-on-year increase of 245.16%, and a net loss of 89.23 million yuan [18] - Nanshan Holdings reported a revenue of 8.40 billion yuan, a year-on-year decrease of 30.35%, and a net loss of 1.77 billion yuan [20] - Hengfeng Information reported a revenue of 227 million yuan, a year-on-year decrease of 53.07%, and a net loss of 86.80 million yuan [21] - Wantong Technology reported a revenue of 1.21 billion yuan, a year-on-year increase of 19.58%, and a net profit of 36.92 million yuan, up 147.08% [22] - Kehua Bio reported a revenue of 1.76 billion yuan, a year-on-year decrease of 27.55%, and a net loss of 641 million yuan [23] - Dongfang Tower reported a revenue of 4.20 billion yuan, a year-on-year increase of 4.79%, and a net profit of 564 million yuan, down 10.97% [24] - Yanpai Co. reported a revenue of 785 million yuan, a year-on-year increase of 8.75%, and a net profit of 42.18 million yuan, down 35.72% [25] - Yongli Co. reported a revenue of 2.24 billion yuan, a year-on-year increase of 10.69%, and a net profit of 22.30 million yuan, down 40.73% [26]

亿帆医药股份有限公司 非经营性资金占用及其他关联 资金往来情况的专项报告 信会师报字[2025]第 ZB10857 号 关于亿帆医药股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 本报告仅供亿帆医药公司为披露 2024 年年度报告的目的使用， 不得用作任何其他目的。 信会师报字[2025]第 ZB10857 号 亿帆医药股份有限公司全体股东： 我们审计了亿帆医药股份有限公司(以下简称"亿帆医药公 司")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZB10854 号的 标准无保留意见审计报告。 亿帆医药公司管理层根据中国证券监督管理委员会《上市公司监 管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监 会公告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南 第 1 号——业务办理》的相关规定编制了后附的 2024 年度非经营性 资金占用及其 ...

亿帆医药股份有限公司 审计报告及财务报表 二○二四年度 亿帆医药股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 三、 | 财务报表附注 | 1-118 | 审计报告 关键审计事项是我们根据职业判断，认为对本期财务报表审计最 为重要的事项。这些事项的应对以对财务报表整体进行审计并形成审 计意见为背景，我们不对这些事项单独发表意见。 审计报告 第 1 页 审计报告 第 2 页 信会师报字[2025]第 ZB10854 号 亿帆医药股份有限公司全体股东： 一、 审计意见 我们审计了亿帆医药股份有限公司（以下简称亿帆医药）财务报 表，包括 2024 年 12 月 31 日的合并及母 ...

亿帆医药股份有限公司 内部控制审计报告 信会师报字[2025]第 ZB10855 号 内部控制审计报告 信会师报字[2025]第 ZB10855 号 亿帆医药股份有限公司全体股东： 按照《 企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了亿帆医药股份有限公司《 以下简称亿帆医药）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《 企业内部控制基本规范》、 企业内部控制应用指引》、 企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是亿帆医药董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内部控制审计报告 第 1 页 四、 财务报告内部控制审计意见 我们认为，亿帆医药于 ...

亿帆医药股份有限公司 募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZB10856 号 关于亿帆医药股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第ZB10856号 亿帆医药股份有限公司全体股东： 我们接受委托，对后附的亿帆医药股份有限公司（以下简称"亿 帆医药公司"）2024年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 亿帆医药公司董事会的责任是按照中国证券监督管理委员会《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第1号——主板上市公司规范运作》以及《深 圳证券交易所上市公司自律监管指南第2号——公告格式》的相关规 定编制募集资金专项报告。这种责任包括设计、执行和维护与募集资 金专项报告编制相关的内部控制，确保募集资金专项报告真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们按照《中国注册会计师其他鉴证业务准则第3101号 ...

申万宏源证券承销保荐有限责任公司关于 亿帆医药股份有限公司 2024 年度募集资金存放与使用情况的 专项核查意见 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、"本 保荐机构"）作为亿帆医药股份有限公司（以下简称"亿帆医药"）2017 年非公开 发行股票募集资金持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》和《深圳证券交易所上市公司自律监管指引第 13 号 ——保荐业务》等有关规定，对亿帆医药 2017 年非公开发行股票募集资金 2024 年存放与使用情况进行了核查，并发表独立意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证监会《关于核准亿帆医药股份有限公司非公开发行股票的批复》（证 监许可【2017】928 号）核准，亿帆医药向特定对象非公开发行人民币普通股（A 股）10,617.65 万股，发行价格为 17.00 元/股，募集资金总额 180,500.00 万元， 扣除保荐 ...

亿帆医药股份有限公司 2024年度独立董事述职报告 2024年度，本人作为亿帆医药股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》《上市公司独立董事管理办法》《上 市公司自律监管指引第1号—主板上市公司规范运作》等相关法律法规、制度及 《公司章程》和公司《独立董事工作制度》等有关规定，在保持独立董事应有 独立性的前提下，勤勉尽责，积极出席公司相关会议，认真审议董事会、下属 委员会及独立董事专门会议的各项议案，充分发挥了独立董事的作用。维护了 全体股东尤其是中小股东的合法权益。现将本人2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 雷新途先生，中国国籍，1972年5月出生，会计学教授，会计学博士。浙江 工业大学任教授、会计系主任、会计学研究所所长。杭氧集团股份有限公司独 立董事。2019年4月24日-2025年2月7日任公司独立董事。 （二）独立性情况说明 作为公司的独立董事，本人及直系亲属均不在公司或其附属企业担任除独 立董事之外的其他职务，也未在公司主要股东处担任任何职务；不直接或间接 持有公司股份，不在直接或间接持有公司已发行 ...